Session » Vasculitis Poster III: Other Vasculitis Syndromes

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2734

A Comparison of Current Practice to New Vasculitis Treatment Guidelines

9:00AM-11:00AM: Abstract Number: 2742

A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts

9:00AM-11:00AM: Abstract Number: 2750

A Serum Metabolomic Analysis in Behcet’s Disease: A Preliminary Study

9:00AM-11:00AM: Abstract Number: 2723

Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group

9:00AM-11:00AM: Abstract Number: 2721

Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study

9:00AM-11:00AM: Abstract Number: 2724

Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases

9:00AM-11:00AM: Abstract Number: 2727

Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study

9:00AM-11:00AM: Abstract Number: 2720

Behcet’s Disease in Southeastern Michigan: A Single Center Comparative Study

9:00AM-11:00AM: Abstract Number: 2719

Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?

9:00AM-11:00AM: Abstract Number: 2733

Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement

9:00AM-11:00AM: Abstract Number: 2730

Clinical Features and Treatment of Central Nervous System Vasculitis Associated with Acute Posterior Multifocal Placoid Pigment Epitheliopathy

9:00AM-11:00AM: Abstract Number: 2746

Comparison between IgG and IgM Type Anti-Alpha-Enolase Antibody in Patients with Behcet’s Disease According to the Disease Severity

9:00AM-11:00AM: Abstract Number: 2740

Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases

9:00AM-11:00AM: Abstract Number: 2726

Differentiating Features of Primary Angiitis of Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Evaluation

9:00AM-11:00AM: Abstract Number: 2749

Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries

9:00AM-11:00AM: Abstract Number: 2716

Gastrointestinal Involvement in Adult IgA Vasculitis (Henoch–Schönlein purpura): Initial Manifestations and Outcomes

9:00AM-11:00AM: Abstract Number: 2748

Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study

9:00AM-11:00AM: Abstract Number: 2738

Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2718

Is Smoking Important in Adult IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 2735

Is There an Association between Adult IgA Vasculitis and Cancer?

9:00AM-11:00AM: Abstract Number: 2717

Late Onset of IgA Vasculitis Is Associated with More Severe Renal Involvement

9:00AM-11:00AM: Abstract Number: 2722

Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases

9:00AM-11:00AM: Abstract Number: 2747

Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 2744

Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 2736

Long-Term Survival in Systemic Necrotizing Vasculitides

9:00AM-11:00AM: Abstract Number: 2739

Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2745

Prevalence of Vasculitides As Extraintestinal Manifestation of Inflammatory Bowel Disease (IBD)

9:00AM-11:00AM: Abstract Number: 2737

Pulmonary Manifestations of Primary Systemic Vasculitides

9:00AM-11:00AM: Abstract Number: 2732

Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2743

Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)

9:00AM-11:00AM: Abstract Number: 2741

Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons

9:00AM-11:00AM: Abstract Number: 2752

Risk of Hospitalizations for Venous Thromboembolism Among Patients with Selected Systemic Vasculitides: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 2728

Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients

9:00AM-11:00AM: Abstract Number: 2729

Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome

9:00AM-11:00AM: Abstract Number: 2731

The Utility of Unbiased Metagenomic Next Generation Sequencing in the Management of Patients with CNS Vasculitis

9:00AM-11:00AM: Abstract Number: 2751

Tocilizumab in the Treatment of Severe and/or Refractory Behcet’s Disease：a Single-Centre Experience in China

9:00AM-11:00AM: Abstract Number: 2725

Understanding Vasculitis Patients’ Ability to Work with Numbers

« View all sessions from this meeting